Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

PURPOSE: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) gefitinib and erlotinib benefit some non–small cell lung cancer (NSCLC) patients, but most do not respond (primary resistance) and those who initially respond eventually progress (acquired resistance). EGFR TKI res...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Naumov, George N., Nilsson, Monique B., Cascone, Tina, Briggs, Alexandra, Straume, Oddbjorn, Akslen, Lars A., Lifshits, Eugene, Byers, Lauren Averett, Xu, Li, Wu, Hua-kang, Jänne, Pasi, Kobayashi, Susumu, Halmos, Balazs, Tenen, Daniel, Tang, Xi M., Engelman, Jeffrey, Yeap, Beow, Folkman, Judah, Johnson, Bruce E., Heymach, John V.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2893040/
https://ncbi.nlm.nih.gov/pubmed/19447865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-2904
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados